To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2376 | Gsk2838232 |
Novel human immune virus (HIV) maturation inhibitor
More description
|
|
| DCC2375 | Gsk-2807 |
Novel potent and selective, SAM-competitive inhibitor of SMYD3
More description
|
|
| DCC2374 | Gsk270822a |
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
|
|
| DCC2373 | Gsk2565363c |
Betulin derivative as antitumor agent
More description
|
|
| DCC2372 | Gsk246053 |
Specific ATPase competitive kinesin-5 inhibitor
More description
|
|
| DCC2371 | Gsk-239512 |
Novel selective histamine H3 receptor antagonist
More description
|
|
| DCC2370 | Gsk237701a |
Novel I-kappa-B kinase-3 (IKK3) inhibitor
More description
|
|
| DCC2369 | Gsk2263167 |
Novel S1P1 receptor agonist
More description
|
|
| DCC2368 | Gsk2256294a |
Novel highly potent, reversible soluble epoxide hydrolase (sEH) inhibitor, exhibiting potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET, attenuating cigarette smoke-induced inflammation by both i
More description
|
|
| DCC2367 | Gsk223 |
Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway
More description
|
|
| DCC2366 | Gsk2220400a |
Inhibitor of insulin receptor, also tageting IGF-1R and ALK
More description
|
|
| DCC2365 | Gsk2188764 |
Novel inhibitor of T. brucei IPMK, partially inhibiting rTbIPMK activity
More description
|
|
| DCC2364 | Gsk2163632a |
Novel insulin-like growth factor 1 receptor inhibitor, binding to a novel region of the GRK active site cleft that could likely be exploited to achieve more selectivity
More description
|
|
| DCC2363 | Gsk2141795 Hydrochloride |
Novel AKT Inhibitor, Enhancing Anti-Tumor Effects in Combination with the MEK Inhibitor
More description
|
|
| DCC2362 | Gsk207040 |
Novel selective non-imidazole histamine H 3 receptor antagonist
More description
|
|
| DCC2361 | Gsk2008607 |
Novel competitive inhibitor of rTbIPMK with respect to Ins(1,4,5)P3
More description
|
|
| DCC2360 | Gsk1997132b |
Novel potent, metabolically stable and centrally penetrant PPARγ partial agonist
More description
|
|
| DCC2359 | Gsk1910364 |
Novel inhibitor of EPHX2 (epoxide hydrolase 2, alias soluble epoxide hydrolase or sEH), up-regulating cytoprotective genes and down-regulating proinflammatory cytokine production
More description
|
|
| DCC2358 | Gsk189254 |
Potent and selective H3 histamine receptor inverse agonist
More description
|
|
| DCC2357 | Gsk1829820a |
Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv
More description
|
|
| DCC2355 | Gsk1723980 |
Novel noncompetitive inhibitor of rTbIPMK
More description
|
|
| DCC2354 | Gsk1452498a |
Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv
More description
|
|
| DCC2353 | Gsk1452496a |
Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv
More description
|
|
| DCC2352 | Gsk1379767a |
Novel dual inhibitor of BPTF and Brd4
More description
|
|
| DCC2351 | Gsk1370319a |
Novel specific P2X(7) receptor antagonist
More description
|
|
| DCC2350 | (BrMT)2 |
Non-peptidic snail toxin; Activator of the Kv1.1 potassium ion channel
More description
|
|
| DCC2349 | Gsk-1264 |
Novel allosteric inhibitor of human immunodeficiency virus (HIV) integrase, blocking viral replication and abnormal multimerization involving specific protein domains
More description
|
|
| DCC2348 | Gsk1180781a |
Novel selective inhibitor of MmpL3 mutation
More description
|
|
| DCC2347 | Gsk1104252a |
Potent and selective GPR119 agonist
More description
|
|
| DCC2346 | Gsk1030058a |
Novel inhibitor of polo-like kinase
More description
|
|